New PARP1 inhibitor targets Hard-to-Treat cancers

NCT ID NCT07695142

Not yet recruiting Disease control Sponsor: Haisco Pharmaceutical Group Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This trial tests an experimental drug called HSK46256, which blocks a protein called PARP1 that helps repair DNA in cancer cells. The study includes adults with advanced solid tumors who have not responded to standard treatments. Researchers aim to find the safest dose and check whether the drug can shrink tumors or slow their growth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HSK46256 (a PARP1 inhibitor)
What this could lead to: If successful, this could provide a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong: This is an early phase 1 trial, so the drug may not prove safe or effective. Side effects and limited benefit are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR (PHASE 1)

Contacts and locations

Show contact details

Locations

Fudan University Shanghai Cancer Center

Shanghai, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.